SEARCH

SEARCH BY CITATION

References

  • Allison, M.C., Howatson, A.G., Torrance, C.J., Lee, F.D. & Russell, R.I. (1992). Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. New Engl. J. Med., 327, 749754.
  • Battistini, B., Botting, R. & Bakhle, Y.S. (1994). COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect., 7, 501512.
  • Bertenshaw, S.R., Talley, J.J., Rogier, D.J., Graneto, M.J., Rogers, R.S., Kramer, S.W., Penning, T.D., Koboldt, C.M., Veenhuizen, A.W., Zhang, Y. & Perkins, W.E. (1995). 3,4-Diarylthiophenes are selective COX-2 inhibitors. Bioorg. Med. Chem. Lett., 5, 29192922.
  • Brideau, C., Kargman, S., Liu, S., Dallob, A.L., Ehrich, E.W., Rodger, I.W. & Chan, C.-C. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res., 45, 6874.
  • Carr, D.P., Henn, R., Green, J.R. & Bottcher, I. (1986). Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. Agents and Actions, 19, 5/6 374375.
  • Chan, C.-C., Boyce, S., Brideau, C., Ford-Hutchinson, A.W., Gordon, R., Guay, D., Hill, R., Li, C.-S., Mancini, J., Penneton, M., Prasit, P., Rasori, R., Riendeau, D., Roy, P., Tagari, P., Vickers, P., Wong, E. & Rodger, I.W. (1995). Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther., 274, 15311537.
  • Clarke, G.D., Macpherson, I.S., Petrone, G. & Spangler, R.S. (1994). Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation. Eur. J. Pharmacol., 257, 103108.
  • Copeland, R.A., Williams, J.M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S. & Trzaskos, J.M. (1994). Mechanism of selective inhibition of the inducible isoform or prostaglandin G/H synthase. Proc. Natl. Acad. Sci. U.S.A., 91, 1120211206.
  • Cromlish, W.A., Payette, P., Culp, S.A., Ouellet, M., Percival, M.D. & Kennedy, B.P. (1994). High-level expression of active human cyclooxygenase-2 in insect cells. Arch. Biochem. Biophys., 314, 193199.
  • Engelhardt, G., Homma, D., Schlegel, K., Utzmann, R. & Schnitzler, C. (1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-storoidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res., 44, 423433.
  • Engelhardt, G., Bogel, R., Schnitzler, C. & Utzmann, R. (1996). Meloxicam: Influence on Arachidonic Acid Metabolism. Part 1. In Vitro findings. Biochem. Pharmacol., 51, 2128.
  • Funk, C.D., Funk, L.B., Kennedy, M.E., Pong, A.S. & Fitzgerald, G.A. (1991). Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J., 5, 23042312.
  • Futaki, N., Hamasaka, Y., Takahashi, S., Higushi, S. & Otomo, S. (1993a). Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol., 45, 753755.
  • Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H. & Otomo, S. (1993b). NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol., 24, 105110.
  • Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S. & Otomo, S. (1994). NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins, 47, 5559.
  • Gans, K.R., Galbraith, W., Roman, R.J., Haber, S.B., Kerr, J.S., Schmidt, W.K., Smith, C., Hewes, W.E. & Ackerman, N.R. (1990). Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther., 254, 180187.
  • Gauthier, J.-Y., Leblanc, Y., Black, W.C., Chan, C.-C., Cromlish, W.A., Gordon, R., Kennedy, B.P., Lau, C.K., Leger, S., Wang, Z., Ethier, D., Guay, J., Mancini, J., Riendeau, D., Tagari, P., Vickers, P., Wong, E. & Prasit, P. (1996). Synthesis and evaluation of 2,3-diarylthiophenes as selective COX-2 inhibitors. Part II: Replacing the heterocycle. Bioorg. Med. Chem. Lett., 6, 8792.
  • Glaser, K., Sung, M.L., O'Neill, K., Belfast, M., Hartman, D., Carlson, R., Kreft, A., Kubrak, D., Hsiao, C.L. & Weichman, B. (1995). Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol., 281, 107111.
  • Griswold, D.E. & Adams, J.L. (1996). Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med. Res. Rev., 16, 181206.
  • Harada, Y., Hatanaka, K., Kawamura, M., Saito, M., Ogino, M., Majima, M., Ohno, T., Ogino, K., Yamamoto, K., Taketani, Y., Yamamoto, S. & Katori, M. (1996). Role of prostaglandin H synthase-2 in prostaglandin E2 formation in rat carrageenin-induced pleurisy. Prostaglandins, 51, 1933.
  • Harris, R.C., Mckanna, J.A., Akai, Y., Jacobson, H.R. & Dubois, R.N. (1994). Cyclooxygenase-2 is associated with the macula densa or rat kidney and increases with salt restriction. J. Clin. Invest., 94, 25042510.
  • Harris Callan, O., So, O.-Y. & Swinney, D.C. (1996). The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J. Biol. Chem., 271, 35483554.
  • Herschman, H.R. (1996). Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299, 125140.
  • Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J. & O'Neill, G. (1996a). Prostaglandin G/H synthase-1 and -2 in rat, dog, monkey, and human gastrointestinal tract tissues: localization, enzyme activity and inhibition by NSAIDs. Gastroenterology, 111, 445454.
  • Kargman, S., Wong, E., Greig, G.M., Falgueyret, J.-P., Cromlish, W., Ethier, D., Yergey, J.A., Riendeau, D., Evans, J.F., Kennedy, B., Tagari, P., Francis, D.A. & O'Neill, G.P. (1996b). The mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. Pharmacol., 52, 11131125.
  • Klein, T., Nusing, R.M., Pfeilschifter, J. & Ullrich, V. (1994). Selective inhibition of cyclooxygenase 2. Biochem. Pharmacol., 48, 16051610.
  • Laine, L., Sloane, R., Ferreti, M. & Cominelli, F. (1995). A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointestinal Endoscopy, 42, 428433.
  • Lands, W.E.M., LETellier, P.R., Rome, L. & Vanderhoek, J.Y. (1974). Regulation of prostaglandin synthesis. In Prostaglandin Synthase Inhibitors. ed. Robinson, H.J. & Vane, J.R. pp. 17, New York: Raven Press.
  • Langenbach, R., Morham, S.G., Tiano, H.F., Loftin, C.D., Ghanayem, B.I., Chulada, P.C., Mahler, J.F., Lee, C.A., Goulding, E.H., Kluckman, K.D., Kim, H.S. & Smithies, O. (1995). Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 83, 483492.
  • Leblanc, Y., Gauthier, J.Y., Ethier, D., Guay, J., Mancini, J., Riendeau, D., Tagari, P., Vickers, P., Wong, E. & Prasit, P. (1995). Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 and COX-1 inhibitors. Bioorg. Med. Chem. Lett., 5, 21232128.
  • Li, J.J., Norton, M.B., Reinhard, E.J., Anderson, G.D., Gregory, S.A., Isakson, P.C., Koboldt, C.M., Masferrer, J.L., Perkins, W.E., Seibert, K., Zhang, Y., Zweifel, B.S. & Reitz, D.B. (1996). Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J. Med. Chem., 39, 18461856.
  • Magni, E. (1993). The effect of nimesulide on prostanoid formation. Drugs, 46, (suppl. 1): 1014.
  • Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C. & Seibert, K. (1994). Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A., 91, 32283232.
  • Melarange, R., Gentry, C., Blower, P.R., Toseland, C.D.N. & Sprangler, R. (1995). Nabumetone, in contrast to etodolac, lacks gastrointestinal irritancy in the rat: assessment by the inflammatory marker, haptoglobin, and blood loss. Inflammo-pharmacology, 3, 259270.
  • Murray, M.D. & Brater, D.C. (1993). Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Toxicol., 32, 435465.
  • Noble, S. & Balfour, J.A. (1996). Meloxicam. Drugs, 51, 424430.
  • Ouellet, M. & Percival, M.D. (1995). Effect of inhibitor timedependency on selectivity towards cyclooxygenase isoforms. Biochem. J., 306, 247251.
  • Percival, M.D., Ouellet, M., Vincent, C., Yergey, J., Kennedy, B.P. & O'Neill, G.P. (1994). Purification and characterization of recombinant human cyclooxygenase-2. Arch. Biochem. Biophys., 315, 111118.
  • Reitz, D.B., Li, J.J., Norton, M.B., Reinhard, E.J., Collins, J.T., Anderson, G.D., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K. & Isakson, P.C. (1994). Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J. Med. Chem., 37, 38783881.
  • Rome, L.H. & Lands, W.E.M. (1975). Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. U.S.A., 72, 48634865.
  • Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L. & Isakson, P. (1994). Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U.S.A., 91, 1201312017.
  • Tavares, I.A., Bishai, P.M. & Bennett, A. (1995). Activity of nimesulide on constitutive and inducible cyclooxygenases. Drug Res., 45, 10931095.
  • Vane, J.R. & Botting, R.M. (1995). New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res., 44, 110.
  • Visco, D., Widmer, R., Shen, F., Orevillo, C., Christen, A., Chan, C.-C., Leger, S., Prasit, P., Therien, M., Wang, Z., Rodger, I. & MAcIntyre, E. (1996). The effects of a selective cyclooxygenase-2 (COX-2) inhibitor on adjuvant-induced arthritis in the rat. Prostaglandins, Leukotrienes & Essential Fatty Acids, 55, Suppl. 1, 122.
  • Wallace, J.L. (1994). Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can. J. Physiol. Pharmacol., 72, 14931498.
  • Wiesenberg-Bottcher, I., Schweizer, A., Green, J.R., Seltenmeyer, Y. & Muller, K. (1989). The pharmacological profile of CGP 28238, a highly potent anti-inflammatory compound. Agents Actions, 26, 240242.
  • Wilkerson, W.W., Copeland, R.A., Covington, M. & Trzaskos, J.M. (1995). Antiinflammatory 4,5-diaryl pyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition. J. Med. Chem., 38, 38953901.
  • Young, J.M., Panah, S., Satchawatcharaphong, C. & Cheung, P.S. (1996). Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A32187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm. Res., 45, 246253.